Cloud Pharmaceuticals Designs New Pro-Drugs for Crohn’s, Ulcerative Colitis

Cloud Pharmaceuticals Designs New Pro-Drugs for Crohn’s, Ulcerative Colitis
Cloud-based drug development company Cloud Pharmaceuticals has designed a novel active pro-drug for the treatment of ulcerative colitis and Crohn's disease. The design of the drug comes from teamwork between experts at Cloud Pharmaceuticals, Ben-Gurion University of the Negev (BGU), and the University of Florida (UF), and results will soon be published in the journal Current Topics in Medicinal Chemistry. Evidence has shown that in severely inflamed mucosa of patients with inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, PLA2 proteins have an increased ac
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *